论文部分内容阅读
本文对126例胸水中找到恶性细胞并由影像学及病理学证实原发肿瘤部位的患者进行对比研究。肺癌占88.9％,乳腺癌占4.75％。分为四组:对照组、化疗组、短小棒状杆菌组(CP)及PJV组。从行为状态的改善、胸水的消失率、恶性细胞阴转率及生存期的比较看,以PJV组最好,胸水消失率PJV组34.5％,CP组为6.25％,化疗组0％。胸水阴转率;PJV组94.3％;CP组33.3％,化疗组0％。平均生存期:PJV组15.5月左右;CP组10.9月左右;化疗组8.1月左右。PJV的副作用可用药物得以控制。全身化疗加局部治疗的平均生存期较单纯局部化疗者为长,其中亦以PJV组最突出。
In this study, 126 patients with malignant cells found in pleural effusions and their imaging and pathology confirmed the location of the primary tumor were compared. Lung cancer accounted for 88.9% and breast cancer accounted for 4.75%. Divided into four groups: control group, chemotherapy group, corynebacterium group (CP) and PJV group. From the improvement of behavioral status, disappearance rate of pleural effusion, malignant cell turnover rate and survival time, the best in PJV group was 34.5% in PJV group, 6.25% in CP group, and 0% in chemotherapy group. The rate of pleural effusion was 93.0% in the PJV group, 33.3% in the CP group, and 0% in the chemotherapy group. The average survival time was 15.5 months in the PJV group, 10.9 months in the CP group, and 8.1 months in the chemotherapy group. The side effects of PJV can be controlled with drugs. The average survival time of systemic chemotherapy plus local treatment was longer than that of local chemotherapy alone, and the PJV group was also the most prominent.